Cargando…
浅析MIDD在抗肿瘤药物临床研究中的应用
The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, a...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346158/ https://www.ncbi.nlm.nih.gov/pubmed/35899446 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.38 |
| _version_ | 1784761584924491776 |
|---|---|
| collection | PubMed |
| description | The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, and disease progression information through modeling and simulation, which can reduce the cost of drug development and improve the efficiency of clinical research. In this essay, Osimertinib and Pembrolizumab are given as examples to illustrate the specific application of MIDD in different phases of clinical research, aiming to provide references for the application of MIDD to guide the clinical research of antitumor drugs. |
| format | Online Article Text |
| id | pubmed-9346158 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93461582022-08-17 浅析MIDD在抗肿瘤药物临床研究中的应用 Zhongguo Fei Ai Za Zhi 肺癌创新药物研发 The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, and disease progression information through modeling and simulation, which can reduce the cost of drug development and improve the efficiency of clinical research. In this essay, Osimertinib and Pembrolizumab are given as examples to illustrate the specific application of MIDD in different phases of clinical research, aiming to provide references for the application of MIDD to guide the clinical research of antitumor drugs. 中国肺癌杂志编辑部 2022-07-20 /pmc/articles/PMC9346158/ /pubmed/35899446 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.38 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
| spellingShingle | 肺癌创新药物研发 浅析MIDD在抗肿瘤药物临床研究中的应用 |
| title | 浅析MIDD在抗肿瘤药物临床研究中的应用 |
| title_full | 浅析MIDD在抗肿瘤药物临床研究中的应用 |
| title_fullStr | 浅析MIDD在抗肿瘤药物临床研究中的应用 |
| title_full_unstemmed | 浅析MIDD在抗肿瘤药物临床研究中的应用 |
| title_short | 浅析MIDD在抗肿瘤药物临床研究中的应用 |
| title_sort | 浅析midd在抗肿瘤药物临床研究中的应用 |
| topic | 肺癌创新药物研发 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346158/ https://www.ncbi.nlm.nih.gov/pubmed/35899446 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.38 |
| work_keys_str_mv | AT qiǎnxīmiddzàikàngzhǒngliúyàowùlínchuángyánjiūzhōngdeyīngyòng AT qiǎnxīmiddzàikàngzhǒngliúyàowùlínchuángyánjiūzhōngdeyīngyòng |